https://charts.traderzeitung.de/phases/US92829J2033 string(1421) "{"isin":"US92829J2033","name":"Dogwood Therapeutics Inc","stock_id_xnas":62792669,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.61,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.53,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-4.9689},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":1.55,"close_at":"2026-09-22 22:57:00","complete":true,"perf_pct":1.3072}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.505,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-2.9032},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Dogwood Therapeutics Aktie News & Nachrichten

[WKN: A40QAB | Symbol: DWTX]

Realtimekurs

Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Dogwood Therapeutics gefunden werden.

Dogwood Therapeutics Nachrichtenticker öffnen

MT Newswires 20.07.2026 15:11 Uhr

Dogwood Therapeutics nimmt erste 200 Patienten in Phase-2b-Studie zu neuropathischen Schmerzen auf

09:10 AM EDT, 20.07.2026 (MT Newswires) -- Dogwood Therapeutics (DWTX) teilte am Montag mit, dass das Unternehmen die ersten 200 Patienten in seine Ph